Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase III Study of Anifrolumab in Chronic and/or Subacute Cutaneous Lupus Erythematosus Refractory or Intolerant to Antimalarials
2023-503692-24-00Phase 3Authorised
- Sponsor
- AstraZeneca
- Start
- Aug 2024
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 32
01
Overview
Phase 3, randomised, double-blind trial in cutaneous lupus erythematosus (CLE) and subacute cutaneous lupus erythematosus (SCLE) comparing Anifrolumab with Placebo (2 arms). Primary endpoint: CLASI-70 response at Week 24. Planned start Aug 2024; status: authorised.
02
Drugs
anifrolumab
03
Conditions
cutaneous lupus erythematosus (CLE)subacute cutaneous lupus erythematosus (SCLE)
Beyond the preview
Go deeper on 2023-503692-24-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-503692-24-00.